ARTICLE | Clinical News
Biosimilar adalimumab: Additional Phase III data
June 20, 2016 7:00 AM UTC
Data from 508 patients with moderate to severe RA despite methotrexate therapy in a double-blind, European Phase III trial showed that 40 mg subcutaneous SB5 every other week led to an ACR20 response...